5-azido-3-oxa-pentyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-galactopyranoside | 195531-52-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-azido-3-oxa-pentyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-galactopyranoside
• 英文别名: [(2R,3R,4R,5R,6S)-5-acetamido-3,4-diacetyloxy-6-[2-(2-azidoethoxy)ethoxy]oxan-2-yl]methyl acetate
• CAS: 195531-52-3
• 化学式: C₁₈H₂₈N₄O₁₀
• 分子量: 460.441
• InChiKey: RYGROQIXTIVQGJ-SFFUCWETSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  32
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  150
• 氢给体数：
  1
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  5-azido-3-oxa-pentyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-galactopyranoside 在 甲醇 、 β-galactosidase from bovine testes 、 sodium phosphate-citrate buffer 、 sodium methylate 作用下， 反应 48.0h， 生成 5-azido-3-oxapentyl 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-α-D-galactopyranoside
  参考文献：
  名称：

  Galactosylation with β-galactosidase from bovine testes employing modified acceptor substrates

  摘要：

  In this study beta 1-3 linked analogues of the T-antigen determinant were sythesized in preparative scale by transgalactosylation using beta-galactosidase from bovine testes to give synthetic antigens. Accepters with modifications of the sugar residue such as alpha-glycosylated spacers, as well as GlcNAc-alpha OR- and 2dGal-alpha OR-substrates opened further possibilities for galactosylation. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00071-0
• 作为产物：
  描述：

  3-oxa-5-O-tosyl-pentyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranoside 在 palladium on activated charcoal 吡啶 、 二环己烷并-18-冠醚-6 、 sodium azide 、 氢气 、 溶剂黄146 作用下， 以 丁酮 为溶剂， 反应 10.0h， 生成 5-azido-3-oxa-pentyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-galactopyranoside
  参考文献：
  名称：

  Galactosylation with β-galactosidase from bovine testes employing modified acceptor substrates

  摘要：

  In this study beta 1-3 linked analogues of the T-antigen determinant were sythesized in preparative scale by transgalactosylation using beta-galactosidase from bovine testes to give synthetic antigens. Accepters with modifications of the sugar residue such as alpha-glycosylated spacers, as well as GlcNAc-alpha OR- and 2dGal-alpha OR-substrates opened further possibilities for galactosylation. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00071-0

文献信息

• NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150315221A1

  公开（公告）日：2015-11-05

  The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics.

  本发明涉及一种二硫化物掩蔽的前药化合物、组合物和方法，这些化合物、组合物和方法可通过还原剂如谷胱甘肽进行生物活化。这种基于二硫化物的化合物、组合物和方法可以用于提供新型前药，例如用作治疗药物。
• Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
  申请人：Sirna Therapeutics, Inc.

  公开号：US10221205B2

  公开（公告）日：2019-03-05

  Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

  本文公开了一种模块化组合物，包括：1）寡核苷酸；2）一种或多种式（I）的四GalNAc配体，它们可以相同或不同；任选地，3）一种或多种连接体，它们可以相同或不同；4）一种或多种独立选自表3的肽，它们可以相同或不同；任选地，5）一种或多种靶向配体、增溶剂、药代动力学增强剂、脂质和/或掩蔽剂。
• NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES
  申请人：Sirna Therapeutics, Inc.

  公开号：US20180079769A1

  公开（公告）日：2018-03-22

  Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3 , which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
• US9624249B2
  申请人：——

  公开号：US9624249B2

  公开（公告）日：2017-04-18
• [EN] NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS ET MÉTHODES DE DÉRIVATION DE KINASES NUCLÉOSIDIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014088923A1

  公开（公告）日：2014-06-12

  The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. The compounds feature a conformationally restricted disulfide phosphotriester moiety to mask anionic charge. The compounds include a 1,2-dithigne moiety.